Novo Nordisk rises as Catalent deal in US nears
** Shares in Novo Nordisk NOVOb.CO rise around 2% after its controlling shareholder said on Saturday it had fulfilled regulatory conditions to acquire Catalent CTLT.N in the U.S.
** The deal involves the sale of three Catalent manufacturing sites to Novo Nordisk
** The conversion of the Catalent sites will provide Novo with much more filling capacity than is currently anticipated, J.P.Morgan analysts say
** This will allow Novo to not only ramp the U.S. supply of Wegovy faster from 2026, but also the global supply of Ozempic and the supply of Wegovy excluding the U.S. also from 2026, the broker adds
** Separately, Novo Nordisk said it plans to invest 8.5 billion Danish crowns ($1.20 billion) in a new plant in Denmark
** Novo Nordisk shares top the Copenhagen blue chip index .OMXC20
($1 = 7.0971 Danish crowns)
Reporting by Boleslaw Lasocki
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
